An oil tanker carrying diesel suffered four external explosions near Dakar, Senegal, its manager said, the third vessel with links to Russia to have been struck over the last few days. Seawater ...

Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound. The ...

Nvidia (NVDA) may post sales of $56.8B next week according to Citi. Multiple firms upgraded their price targets ahead of earnings. Sunrun (RUN) was upgraded to buy by Guggenheim with a $27 price ...

Fintel reports that on November 10, 2025, Leerink Partners upgraded their outlook for Eli Lilly and (NYSE:LLY) from Market Perform to Outperform. Analyst Price Forecast Suggests 0.26% Upside As of ...

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher. The U.S. weight loss drug giant reported ...

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Rising Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is seen as a strong heal‌thc‌a‍re stock that investors can ...

Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, ...

Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S.

Offers a broad portfolio of pharmaceuticals targeting diabetes, oncology, immunology, neuroscience, and other therapeutic areas; key products include Zepbound ...

Eli Lilly stock sank after its second-quarter report due to underwhelming results for a key weight loss drug in its pipeline. Eli Lilly actually posted strong sales and earnings results in Q2 and ...